 Connection
Co-Authors
This is a "connection" page, showing publications co-authored by Thomas Flaig and Eryn Callihan.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
1.250 |
|
|
|
-
Callihan EB, Kuna EM, Eule CJ, Kessler ER, Flaig TW. Practice patterns and outcomes of conventional versus split-dose cisplatin in neoadjuvant ddMVAC in bladder cancer. Bladder Cancer. 2025 Jan-Mar; 11(1):23523735241310388.
Score: 0.967
-
Eule CJ, Warren A, Molina Kuna E, Callihan EB, Kim SP, Flaig TW. Neoadjuvant Cisplatin-based Chemotherapy in Nonmetastatic Muscle-invasive Bladder Cancer: A Systematic Review and Pooled Meta-analysis to Determine the Preferred Regimen. Urology. 2024 06; 188:118-124.
Score: 0.229
-
Kessler ER, Callihan E, Hu J, Eule C, Srivastava G, Kemme DJ, Iruku P, Rana V, Moore J, Schuster SR, Amirault M, Flaig TW, Lam ET. A Phase I/II Clinical Trial of Pembrolizumab and Cabozantinib in Metastatic Renal Cell Carcinoma. Cancer Res Commun. 2023 06; 3(6):1004-1012.
Score: 0.054
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|